EQRx’s Collaboration with Abdul Latif Jameel Health

Ropes & Gray advised EQRx in the deal.

EQRx announced a strategic collaboration with Abdul Latif Jameel Health, part of the international diversified family business of Abdul Latif Jameel. 

Under the agreement, Abdul Latif Jameel Health will become EQRx’s regulatory and commercial partner for two of EQRx’s oncology programs, aumolertinib and sugemalimab, in selected markets throughout the Middle East region, Turkey and all of Africa. 

EQRx is a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at radically lower prices. Launched in January 2020, EQRx is purpose-built, at scale, with a growing catalog of medicines in development in high-cost drug categories and emerging partnerships with leading payers and providers. 

Abdul Latif Jameel health is division of Abdul Latif Jameel dedicated to accelerating access to healthcare for those who need it most. They offer a single relationship solution delivering tailored services to accommodate our partners’ needs – a fully integrated proposition from registration to distribution, and promotion to regulatory services.

The Ropes & Gray team was led by life sciences partner Abigail Gregor (Picture; Boston).

Involved fees earner: Abigail Gregor – Ropes & Gray;

Law Firms: Ropes & Gray;

Clients: EQRx;